Senti Biosciences, Inc. Common Stock (SNTI)
Senti Biosciences, Inc. is a biotechnology company focused on developing programmable cell therapies using synthetic biology. The company's platform integrates genetic engineering and computational design to create advanced cell-based medicines aimed at treating diseases such as cancer, autoimmune disorders, and rare genetic conditions.
Company News
Amerant Bancorp Inc. (AMTB) reported Q1 2025 earnings that missed consensus estimates, causing its stock price to drop 13.09%. Pomerantz LLP is investigating potential securities fraud or other unlawful business practices by the company and its officers/directors.
Several healthcare stocks saw significant price movements in Thursday's pre-market session, with notable gainers including Autonomix Medical, Inspire Veterinary, and Salarius Pharmaceuticals, while Gain Therapeutics, Senti Biosciences, and Aspira Womens Health declined.
Take these actions to diversify your portfolio in 2024 The post Actions for Diversifying Your Penny Stocks Portfolio in 2024 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
The FDA clears Senti Bio's (SNTI) investigational new drug application for SENTI-202 for the treatment of relapsed/refractory hematologic malignancies, including acute myeloid leukemia. Stock rises.